References
- WeissGJHoffBRWhiteheadRPEvaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision makingOnco Targets Ther2015895996725960669
- FramptonGMFichtenholtzAOttoGADevelopment and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingNat Biotechnol201331111023103124142049
- MarshDJTrahairTNMartinJLRapamycin treatment for a child with germline PTEN mutationNat Clin Pract Oncol20085635736118431376
- ChengHPiperdiBZouY335 RICTOR amplification as a novel molecular target for the treatment of lung cancerEur J Cancer201450Suppl 6108109
- BoradMJChampionMDEganJBIntegrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinomaPLoS Genet2014102e100413524550739
- VillaruzLCSocinskiMATemsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7 mutationLung Cancer201483230030124360397
- JännePAShawATPereiraJRSelumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 studyLancet Oncol2013141384723200175
- GoswamiPCRoti RotiJLHuntCRThe cell cycle-coupled expression of topoisomerase IIα during S phase is regulated by mRNA stability and is disrupted by heat shock or ionizing radiationMol Cell Biol1996164150015088657123
- MuellerREParkesRKAndrulisIO’MalleyFPAmplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samplesGenes Chromosomes Cancer200439428829714978790
- DesmedtCDi LeoAde AzambujaEMultifactorial approach to predicting resistance to anthracyclinesJ Clin Oncol201129121578158621422418
References
- WeissGJHoffBRWhiteheadRPEvaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision makingOnco Targets Ther201589596725960669
- Von HoffDDStephensonJJRosenPPilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancersJ Clin Oncol201028334877488320921468
- WeissGJLiangWSDemeureMJA pilot study using next-generation sequencing in advanced cancers: feasibility and challengesPLoS One2013810e7643824204627
- GraySWHicks-CourantKCroninARollinsBJWeeksJCPhysicians’ attitudes about multiplex tumor genomic testingJ Clin Oncol201432131317132324663044
- Recent Article Threatens to Undermine Progress in Precision Medicine2015 Available at: http://www.foundationmedicine.com/2015/04/recent-article-threatens-to-undermine-progress-in-precision-medicine/#more-1181Accessed June 16, 2015
- MarshDJTrahairTNMartinJLRapamycin treatment for a child with germline PTEN mutationNat Clin Pract Oncol20085635736118431376
- ChengHPiperdiBZouY335 RICTOR amplification as a novel molecular target for the treatment of lung cancerEur J Cancer201450Suppl 6108109
- BoradMJChampionMDEganJBIntegrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinomaPLoS Genet2014102e100413524550739
- PrenenHTejparSVan CutsemENew strategies for treatment of KRAS mutant metastatic colorectal cancerClin Cancer Res201016112921292620460490
- KnickelbeinKZhangLMutant KRAS as a critical determinant of the therapeutic response of colorectal cancerGenes Dis20152141225815366
- D’InceccoAAndreozziMLudoviniVPD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patientsBr J Cancer201511219510225349974
- BraseJCSchmidtMFischbachTERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and predictionClin Cancer Res20101682391240120371687
- OdaMArakawaYKanoHQuantitative analysis of topoisomerase IIα to rapidly evaluate cell proliferation in brain tumorsBiochem Biophys Res Commun2005331497197615882973